##semicolon##
systemic sclerosis; skin fibrosis; vascular dysfunction; TGF-β; platelet-derived growth factor; thrombospondin-1; modified Rodnan Skin Score; nailfold capillaroscopy.##submission.citations##
1. Affandi AJ, Radstake TRDJ, Marut W. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment. Seminars in Immunopathology. 2015;37:475–487. doi:10.1007/ s00281-015-0506-4.
2. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. The Journal of Rheumatology. 1993;20(11):1892–1896.
3. Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nature Reviews Rheumatology. 2010;6:578–587. doi:10.1038/ nrrheum.2010.104.
4. Denton CP, et al. The 2024 British Society for Rheumatology guideline for management of systemic sclerosis. Rheumatology. 2024;63(11):2956–2975. doi:10.1093/rheumatology/keae394.
5. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. The Journal of Dermatology. 2010;37(1):11–25. doi:10.1111/j.1346-8138.2009.00738.x.
6. Lambova SN, Müller-Ladner U. Nailfold capillaroscopy in systemic sclerosis – state of the art: the evolving knowledge about capillaroscopic abnormalities in systemic sclerosis. Journal of Scleroderma and Related Disorders. 2019;4(3):200–211.
7. Murphy-Ullrich JE, Suto MJ. Thrombospondin-1 regulation of latent TGF-β activation: a therapeutic target for fibrotic disease. Matrix Biology. 2018;68–69:28–43. doi: 10.1016/j.matbio. 2017.12.009.
8. Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nature Reviews Rheumatology. 2010;6:453–460. doi:10.1038/nrrheum.2010.102.
9. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. The Journal of Clinical Investigation. 2007;117(3):557–567. doi:10.1172/JCI31139.